Obermatt
See Similar Stocks →

AbCellera Biologics

NSQ:ABCL · CA00288U1066
Life Sciences Tools & ServicesSmall

360

19
Profit price76
Owner Earnings Yield1
Dividend Yield1
Price/Sales5
Price/Book56
Return on Capital14
Cash Return on Capital27
Return on Equity32
EBIT Margin1
Gross Profitability1
Accruals48
Owner Earnings Margin1
Sales growth8
Profit growth9
Reinvestment79
Price momentum86
Debt load71
Refinancing73
Debt Payback1
Liquidity59
Analyst ratings78
Opinion Changes90
Price Target Upside93
Market mood22
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

AbCellera Biologics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryCanada
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2012
Employees544
Websiteabcellera.com
ISINCA00288U1066
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
EndocrinologyRheumatologyHealth DiagnosticsDermatologyArtificial IntelligenceImmunologyBiotechnologyMachine LearningMedicalTherapeutics

Description

AbCellera Biologics Inc. (‘AbCellera’), a clinical-stage biotechnology company, focuses on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. The company has built a platform for advancing anti…

Analysis

Weak and unloved

AbCellera Biologics Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
45
2023202420252026

All-time high

91

Jan 2023

All-time low

29

Mar 2026

Average rank

63

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
5
5
17
Price/Earnings
71
93
93
95
Price/Book
56
83
70
88
Dividend Yield
1
1
1
1
Value (overall)
17
38
33
89

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare AbCellera Biologics with its peers
CorMedix
NMQ:CRMD
95
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BridgeBio Pharma
NSQ:BBIO
26
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
OmniAb
NMQ:OABI
61
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Entrada Therapeutics
NMQ:TRDA
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioCryst Pharmaceuticals
NSQ:BCRX
52
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Amylyx Pharmaceuticals
NSQ:AMLX
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →